The efficacy of many drugs with low water-solubility is often limited by their potential to reach therapeutic concentrations at the site of action. Our promising and proven approach to overcome this problem is the development of colloidal drug delivery systems, called NanoMorph.

Using this technology the coarse crystalline drug substances are transformed into a nanodispersed amorphous state, without any physical milling or grinding procedures. It leads to the preparation of amorphous nanoparticles.

NanoMorph technology can in this way help pharmaceutical companies to exploit the full potential of their drug substances. Improved dissolution kinetics, enhanced bioavailability and a broad range of unique dosage forms, make NanoMorph the technology of choice, both for NCE`s and for LCM. This has clearly been proven by several feasibility studies performed successfully both in-house with generic drug substances as well as externally in close collaboration with other pharmaceutical companies.

Why not contact us NOW to find out more about drug delivery by NanoMorph and how we can work successfully together from early feasibility studies through development to full-scale production?